Alnylam Pharmaceuticals, Inc. ranks in an above-average position in its peer group, with growth as the main structural strength, while valuation offers limited differentiation versus peers. The market setup has weakened, with clear trend damage and relative performance under pressure.
Peer-relative scores, weakest to strongest
Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics for rare genetic, cardio-metabolic, and hepatic diseases. The company is a leader in commercializing RNAi-based medicines with a growing portfolio and global reach.
Top-tier capital returns—ROIC at 65.3% and revenue growth of nearly 85% year-over-year—position Alnylam as a standout in biotech efficiency and expansion. Yet, the premium valuation (0/100) remains under scrutiny, as market confidence and stability risks, evidenced by a -42.5% drawdown, keep the premium under pressure.
Internally, a stability score of 28/100 signals persistent risk aversion among investors, while a 38.4% one-year volatility—well above sector median—reflects ongoing equity price fluctuations despite strong operational delivery. The max drawdown of -42.5% shows how quickly sentiment can reverse. Management’s FY2026 revenue guidance of $4.9–5.3bn and a robust TTR franchise outlook are positive signals, but these remain secondary to the core issue: market confidence has not stabilized, and volatility continues to weigh on the equity story.
Recent external context complicates the case rather than resolving it. Alnylam’s return to profitability (EPS $1.41) and aggressive revenue guidance support the execution story, and commercial momentum outpaces most direct competitors. However, the competitive RNAi landscape and ongoing regulatory dependencies mean the premium has not yet found a stable floor—external stressors still echo the internal fragility.
Relative to peers, Alnylam’s combination of profitability, capital efficiency, and ambitious guidance is rare. While some, like Zealand Pharma, show comparable growth, most peers either lack profitability (Natera, Tempus AI) or deliver lower growth (argenx, DraftKings). The severity of confidence and stability risks is more pronounced than for many peers, but is partly driven by factors more specific to Alnylam’s rapid expansion and pipeline exposure.
A more defensible premium would require market confidence to stabilize and volatility to normalize, as well as sustained delivery on aggressive revenue and profitability guidance. Supporting improvement would include achieving regulatory milestones on schedule. Until then, Alnylam carries a valuation not yet fully anchored.
Break down ALNY's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.